Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayBHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ 2CINL24232UP1989GOI010542 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NIL 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: SANDIP KUMAR LAL Designation: DEPUTY GENERAL MANAGER EmailId: sklalacs@yahoo.co.in Name of the Chief Financial Officer: NIL Designation: NIL EmailId: sklalacs@yahoo.co.in Date: 21/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

15 Apr 2019

21.91

1.06%

Corp. Note

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Shareholding for the Period Ended March 31, 2019

BSE India

Bharat Immunologicals & Biologicals Corporation Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here

Bharat Immunological & Biologicals Corporation Ltd.

15 Apr 2019

21.91

1.06%

Corp. Note

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Statement Of Investor Complaints For The Quarter Ended March 2019

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- SANDIP KUMAR LALDesignation :- Company Secretary and Compliance Officer

Bharat Immunological & Biologicals Corporation Ltd.

11 Apr 2019

21.91

1.06%

Corp. Note

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Outcome of Board Meeting

BSE India

In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended March 2019 duly approved by the Board of the Company in its Meeting on 11.04.2019. This submission of UAFR will succeeded by XBRL filing as per the requirement of Exchange. Bharat Immunologicals & Biologicals Corporation Ltd

pdf

Bharat Immunological & Biologicals Corporation Ltd.

11 Apr 2019

21.91

1.06%

Annual Report

Annual report for Bharat Immunological & Biologicals Corporation Ltd. for FY-2019

pdf

Bharat Immunological & Biologicals Corporation Ltd.

07 Apr 2019

21.91

1.06%

Corp. Note

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Certificate From Practicing Company Secretary Under Regulation …

BSE India

In pursuance of Regulation 40 of the LODR with Stock Exchange, please find attached the Certificate from Practicing Company Secretary for the half year ended on 31st March 2019. It is requested to take the above on record please.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

07 Apr 2019

21.91

1.06%

Corp. Note

Bharat Immunologicals & Biologicals Corporation Ltd - 524663 - Compliance Certificate Under Regulation 7(3) Of Securities …

BSE India

Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is submitted the Certificate duly signed by M/s MAS Services Ltd, Share Transfer Agent and the Company Secretary of Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) for the year ending on 31.03.2019 for information and record please.

pdf

Bharat Immunological & Biologicals Corporation Ltd.

04 Apr 2019

21.91

1.06%

Corp. Note

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ - 524663 - Board Meeting Intimation for Intimation Of Date …

BSE India

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/04/2019 ,inter alia, to consider and approve Pursuant to the Regulation 29 and other applicable Regulation(s) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is informed that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 11th April 2019, to approve and take on record the Un-audited Quarterly Financial Results of the Company for the quarter ended 31st March 2019.

pdf

No results found

Is Bharat Immunological & Biologicals Corporation Ltd. worth buying?

135 Votes:

Buy 69.63%

Sell 14.81%

Hold 15.56%